FLUNIFLOR INJECTION

Χώρα: Μαλαισία

Γλώσσα: Αγγλικά

Πηγή: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Δραστική ουσία:

FLORFENICOL; FLUNIXIN MEGLUMINE

Διαθέσιμο από:

RANGE PHARMA SDN. BHD.

INN (Διεθνής Όνομα):

FLORFENICOL; FLUNIXIN MEGLUMINE

Μονάδες σε πακέτο:

100.00 ml

Κατασκευάζεται από:

RANGE PHARMA SDN. BHD.

Αρχείο Π.Χ.Π.

FLUNIFLOR INJECTION
DESCRIPTION AND COMPOSITION
FLUNIFLOR is a light yellow to yellow clear broad spectrum antibiotic
injectable solution. Each liter contains 300 g of Florfenicol,
16.5g Flunixin (as meglumine), 250 g N-MethylPpyrollidone, 150g
Propylene Glycol and q.s. with Polyethylene Glycol 400 as its
excipients.
PHARMACODYNAMICS
Florfenicol is a synthetic broad spectrum antibiotic effective against
most Gram-positive and Gramnegative bacteria isolated from
domestic animals. Florfenicol acts by inhibiting bacterial protein
synthesis at the ribosomal level and is bacteriostatic. Laboratory
tests
have shown that florfenicol is active against the most commonly
isolated bacterial pathogens involved in bovine respiratory disease
which include _Mannheimia haemolytica, Pasteurella multocida _and
_Histophilus somni_.
Florfenicol is considered to be a bacteriostatic agent, but _in vitro
_studies of florfenicol demonstrate bactericidal activity against
_Mannheimia haemolytica_, _Pasteurella multocida _and _Histophilus
somni_.
Flunixin meglumine is a non-steroidal anti-inflammatory drug with
analgesic and antipyretic activity. Flunixin meglumine acts as a
reversible non-selective inhibitor of cyclo-oxygenase (both COX 1 and
COX 2 forms), an important enzyme in the arachidonic acid
cascade pathway which is responsible for converting arachidonic acid
to cyclic endoperoxides. Consequently, synthesis of
eicosanoids,
important mediators of the inflammatory process involved in central
pyresis, pain perception and tissue inflammation, is inhibited.
Through its effects on the arachidonic acid cascade, flunixin also
inhibits the production of thromboxane, a potent platelet pro-
aggregator and vasoconstrictor which is released during blood
clotting. Flunixin exerts its antipyretic effect by inhibiting
prostaglandin E2 synthesis in the hypothalamus. Although flunixin has
no direct effect on endotoxins after they have been produced, it
reduces prostaglandin production and hence reduces the many effects of
the prostaglandin cascade.